longer studies in disease models (for example, kidney aging) suggest benefits at defined doses, but comprehensive long-term safety pharmacology remains sparse in the public domain
Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S (2008) Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy
But a consistent thread in negative reviews describes slow response times, difficulty reaching support when issues arise, and limited options for resolution when problems occur
GHK-Cu is not FDA-approved as a drug for any specific therapeutic indication
At Pellecome in Gladstone, NJ, we believe in restoring the bodys natural capacity to heal, energize, and care for itself